Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Achillion Pharma Enters into Licensing Agreement with Ora 11
Equity Offering 12
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc – Key Competitors 20
Achillion Pharmaceuticals Inc – Key Employees 21
Achillion Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Achillion reports second quarter 2018 financial results 23
May 02, 2018: Achillion Reports First Quarter 2018 Financial Results and Management Transition 25
Feb 22, 2018: Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results 27
Nov 01, 2017: Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 29
Aug 08, 2017: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 30
May 04, 2017: Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs 33
Feb 23, 2017: Achillion Reports 2016 Fourth Quarter and Year-End Financial Results 35
Corporate Communications 37
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer 37
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer 38
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer 39
Sep 11, 2017: Achillion Announces Strengthening of Management Team 40
Jul 10, 2017: Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change 41
Product News 42
09/11/2017: Janssen to Discontinue Hepatitis C Development Program 42
02/26/2018: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy 43
Product Approvals 44
Nov 06, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 44
Clinical Trials 45
Jul 10, 2018: Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D 45
Dec 20, 2017: Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 46
Dec 18, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 47
Nov 14, 2017: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 48
Nov 01, 2017: Achillion Provides Update on ACH-4471 50
Nov 01, 2017: Achillion Provides Update on ACH-5228 52
Oct 23, 2017: Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting 53
Apr 24, 2017: Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178) 54
Apr 22, 2017: Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 55
Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria 56
Apr 06, 2017: New data for simeprevir will be presented at EASL’s International Liver Congress 2017 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharma Enters into Licensing Agreement with Ora 11
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc, Key Competitors 20
Achillion Pharmaceuticals Inc, Key Employees 21
List of Figures
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9